

2014 Sep;2(5):709-713.

7: Kishi Y, Shimada K, Nara S, Esaki M, **Hiraoka N**, Kosuge T. Basing treatment strategy for non-functional pancreatic neuroendocrine tumors on tumor size. **Ann Surg Oncol.** 2014 Sep;21(9):2882-8.

8: Qiu Y, Shimada K, **Hiraoka N**, Maeshiro K, Ching WK, Aoki-Kinoshita KF, Furuta K. Knowledge discovery for pancreatic cancer using inductive logic programming. **IET Syst Biol.** 2014 Aug;8(4):162-8.

9: Inagawa Y, Yamada K, Yugawa T, Ohno S, **Hiraoka N**, Esaki M, Shibata T, Aoki K, Saya H, Kiyono T. A human cancer xenograft model utilizing normal pancreatic ductepithelial cells conditionally transformed with defined oncogenes. **Carcinogenesis.** 2014 Aug;35(8):1840-6.

10: Hayashi T, Horiuchi A, Sano K, Hiraoka N, Ichimura T, Sudo T, Ishiko O, Yaegashi N, Aburatani H, Konishi I. Potential diagnostic biomarkers: differential expression of LMP2/β1i and cyclin B1 in human uterine leiomyosarcoma. **Tumori.** 2014 Jul-Aug;100(4):99e-106e.

11: Yamazaki K, Masugi Y, Effendi K, Tsujikawa H, **Hiraoka N**, Kitago M, Shinoda M, Itano O, Tanabe M, Kitagawa Y, Sakamoto M. Upregulated SMAD3 promotes epithelial-mesenchymal transition and predicts poor prognosis in pancreatic ductal adenocarcinoma. **Lab Invest.** 2014 Jun;94(6):683-91.

12: Watabe Y, Mori T, Yoshimoto S, Nomura T, Shibahara T, Yamada T, **Honda K**. Copy number increase of ACTN4 is a prognostic indicator in salivary gland carcinoma. **Cancer Med.** 2014 Jun;3(3):613-22.

13: Tanaka N, Yamashita T, Yamamoto S, Matsunobu T, Tsuda H, **Honda K**, Yamada T, Tamai S, Shiotani A. Histological growth pattern of and alpha-actinin-4 expression in thyroid cancer. **Anticancer Res.** 2014 Jun;34(6):3157-63.

14: Kondo S, Shimazu T, **Morizane C**, Hosoi H, Okusaka T, Ueno H. A retrospective analysis of factors associated with selection of end-of-life care and actual place of death for patients with cancer. **BMJ Open.** 2014 May 2;4(5).